Rabies immunoglobulin

Last updated

Rabies immunoglobulin
Clinical data
Trade names Imogam Rabies-HT, Kedrab, Hyperrab, others
AHFS/Drugs.com Monograph
Pregnancy
category
Routes of
administration 		Intramuscular injection
ATC code
Legal status
Legal status
Identifiers
DrugBank
ChemSpider
  • none
UNII

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. [10] It is used to prevent rabies following exposure. [10] It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine. [10] It is given by injection into the site of the wound and into a muscle. [10] It is not needed in people who have been previously vaccinated against rabies. [11]

Contents

Common side effects include pain at the site of injection, fever, and headache. [10] Severe allergic reactions such as anaphylaxis may rarely occur. [12] Use during pregnancy is not known to harm the baby. [10] It works by binding to the rabies virus before it can enter nerve tissue. [10] After the virus has entered the central nervous system, rabies immunoglobulin is no longer useful. [10]

The use of rabies immunoglobulin in the form of blood serum dates from 1891. [13] Use became common within medicine in the 1950s. [14] It is on the World Health Organization's List of Essential Medicines. [15] Rabies immunoglobulin is expensive and hard to come by in the developing world. [16] In the United States it is estimated to be more than US$1,000.00 per dose. [17] It is made from the blood plasma of people or horses who have high levels of the antibody in their blood. [10] [17] The horse version is less expensive but has a higher rate of side effects. [17] [14]

Medical uses

Rabies immunoglobulin (RIG) is indicated for the passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and in combination with a rabies vaccine. [18] [19] [1]

Society and culture

Names

There are three versions of rabies immunoglobulin licensed and available in the US. [20] Imogam Rabies-HT is produced by Sanofi Pasteur. [6] Kedrab is produced by Kedrion Biopharma. [18] [7] Hyperrab is produced by Grifols. [8]

Imogam Rabies-HT and Kedrab have a nominal potency of 150 IU/mL while Hyperrab has a nominal potency of 300 IU/mL and requires smaller dosing. All three versions are used for post-exposure [21] and indicate local infusion at the wound site with additional amount intramuscularly at a site distant from vaccine administration. [22]

Kamrab is approved for medical use in Australia. [1]

Related Research Articles

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

Rho(D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. It is often given both during and following pregnancy. It may also be used when RhD-negative people are given RhD-positive blood. It is given by injection into muscle or a vein. A single dose lasts 12 weeks. It is made from human blood plasma.

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

The MMRV vaccine combines the attenuated virus MMR vaccine with the addition of the varicella (chickenpox) vaccine. The MMRV vaccine is typically given to children between one and two years of age.

<span class="mw-page-title-main">Diphtheria antitoxin</span> Treatment for diphtheria

Diphtheria antitoxin (DAT) is a medication made up of antibodies used in the treatment of diphtheria. It is no longer recommended for prevention of diphtheria. It is administered through injection into a vein or muscle.

In immunology, passive immunity is the transfer of active humoral immunity of ready-made antibodies. Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin are transferred to non-immune persons through blood products that contain antibodies, such as in immunoglobulin therapy or antiserum therapy. Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response, or to reduce the symptoms of ongoing or immunosuppressive diseases. Passive immunization can be provided when people cannot synthesize antibodies, and when they have been exposed to a disease that they do not have immunity against.

<span class="mw-page-title-main">Pneumococcal vaccine</span> Vaccine to prevent infection by the bacteria Stretococcus pneumoniae

Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.

<span class="mw-page-title-main">Hepatitis B vaccine</span> Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

<span class="mw-page-title-main">Hepatitis A vaccine</span> Vaccine to prevent hepatitis A

Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in Europe in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines.

<span class="mw-page-title-main">Rabies vaccine</span> Vaccines to prevent rabies in humans and animals

The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual.

<span class="mw-page-title-main">Rabies</span> Deadly viral disease, transmitted through animals

Rabies is a viral disease that causes encephalitis in humans and other mammals. It was historically referred to as hydrophobia due to the symptom of panic when presented with liquids to drink. Early symptoms can include fever and abnormal sensations at the site of exposure. These symptoms are followed by one or more of the following symptoms: nausea, vomiting, violent movements, uncontrolled excitement, fear of water, an inability to move parts of the body, confusion, and loss of consciousness. Once symptoms appear, the result is virtually always death. The time period between contracting the disease and the start of symptoms is usually one to three months but can vary from less than one week to more than one year. The time depends on the distance the virus must travel along peripheral nerves to reach the central nervous system.

<span class="mw-page-title-main">Tick-borne encephalitis vaccine</span> Vaccine against tick-borne encephalitis

Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis (TBE). The disease is most common in Central and Eastern Europe, and Northern Asia. More than 87% of people who receive the vaccine develop immunity. It is not useful following the bite of an infected tick. It is given by injection into a muscle.

<span class="mw-page-title-main">Rubella vaccine</span> Vaccine used to prevent rubella

Rubella vaccine is a vaccine used to prevent rubella. Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome. When there is a low level of childhood immunization in a population it is possible for rates of congenital rubella to increase as more women make it to child-bearing age without either vaccination or exposure to the disease. Therefore, it is important for more than 80% of people to be vaccinated. By introducing rubella containing vaccines, rubella has been eradicated in 81 nations, as of mid-2020.

Hepatitis B immunoglobulin (HBIG) is a human immunoglobulin that is used to prevent the development of hepatitis B and is used for the treatment of acute exposure to HBsAg.

Vaccinia immune globulin (VIG) is made from the pooled blood of individuals who have been inoculated with the smallpox vaccine. The antibodies these individuals developed in response to the smallpox vaccine are removed and purified. This results in VIG. It can be administered intravenously. It is used to treat individuals who have developed progressive vaccinia after smallpox vaccination.

Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s, but was hindered by the need to create immunity against all four dengue serotypes. As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga.

Immunoglobulin therapy is the use of a mixture of antibodies to treat several health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a more specific immunoglobulin is not available. Depending on the formulation it can be given by injection into muscle, a vein, or under the skin. The effects last a few weeks.

<span class="mw-page-title-main">Anti-tetanus immunoglobulin</span> Medication made up of antibodies against the tetanus toxin

Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid, or have HIV/AIDS. It is used to treat tetanus along with antibiotics and muscle relaxants. It is given by injection into a muscle. Part of the dose is injected at the site of the wound.

<span class="mw-page-title-main">Rabies in Haiti</span> Viral disease in Haiti

Rabies is a viral disease that exists in Haiti and throughout the world. It often causes fatal inflammation of the brain in humans and other mammals, such as dogs and mongooses in Haiti. The term "rabies" is derived from a Latin word that means "to rage"; rabid animals sometimes appear to be angry. Early symptoms can include fever and tingling at the site of exposure, followed by one or more of the following symptoms: violent movements, uncontrolled excitement, fear of water, an inability to move parts of the body, confusion, and loss of consciousness. Once symptoms appear, death is nearly always the outcome. The time period between contracting the disease and showing symptoms is usually one to three months; however, this time period can vary from less than a week to more than a year. The time between contraction and the onset of symptoms is dependent on the distance the virus must travel to reach the central nervous system.

References

  1. 1 2 3 4 "Kamrab". Therapeutic Goods Administration (TGA). 23 August 2021. Retrieved 10 September 2021.
  2. ↑ "Kamrab PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
  3. ↑ "Imogam PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
  4. ↑ "Hyperrab S/D PI". Health Canada. 25 April 2012. Retrieved 10 September 2021.
  5. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada . 14 October 2020. Retrieved 17 April 2024.
  6. 1 2 "Imogam Rabies-HT - human rabies virus immune globulin injection, solution". DailyMed. Retrieved 24 March 2020.
  7. 1 2 "Kedrab- human rabies virus immune globulin injection, solution". DailyMed. Retrieved 24 March 2020.
  8. 1 2 "Hyperrab (rabies immune globulin- human injection, solution". DailyMed. Retrieved 24 March 2020.
  9. ↑ "Hyperrab S/D (rabies immune globulin- human injection". DailyMed. Retrieved 10 September 2021.
  10. 1 2 3 4 5 6 7 8 9 "Rabies Immune Globulin". The American Society of Health-System Pharmacists. Archived from the original on 18 March 2011. Retrieved 8 January 2017.
  11. ↑ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 398. hdl: 10665/44053 . ISBN   9789241547659.
  12. ↑ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 869. ISBN   9780857111562.
  13. ↑ Rupprecht CE, Plotkin SA (2013). "Rabies Vaccines". In Plotkin SA, Orenstein WA, Offit PA (eds.). Vaccines (6th ed.). [Edinburgh]: Elsevier/Saunders. p. 659. ISBN   978-1455700905. Archived from the original on 9 January 2017.
  14. 1 2 Jong EC, Zuckerman JN (2004). Travelers' Vaccines. PMPH-USA. p. 205. ISBN   9781550092257. Archived from the original on 9 January 2017.
  15. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  16. ↑ Tintinalli JE (2010). Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli)) (7 ed.). New York: McGraw-Hill Companies. p. 1054. ISBN   978-0-07-148480-0.
  17. 1 2 3 Research Advances in Rabies. Academic Press. 2011. p. 351. ISBN   9780123870414. Archived from the original on 9 January 2017.
  18. 1 2 "Kedrab". U.S. Food and Drug Administration (FDA). 21 March 2018. Retrieved 7 June 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  19. ↑ "Summary Basis for Regulatory Action - Kedrab". FDA. 23 August 2017.
  20. ↑ "Vaccine and Immune Globulin Availability". Centers for Disease Control and Prevention (CDC). 26 February 2020. Retrieved 24 March 2020.
  21. ↑ "WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans" (PDF). World Health Organization (WHO). 2014.
  22. ↑ "Rabies Biologics | Specific Groups | CDC". www.cdc.gov. 15 January 2021. Retrieved 18 November 2022.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.